Oncternal Therapeutics, Inc.

NasdaqCM:ONCT Stock Report

Market Cap: US$1.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Oncternal Therapeutics Management

Management criteria checks 3/4

Oncternal Therapeutics' CEO is Jim Breitmeyer, appointed in Jun 2019, has a tenure of 5.5 years. total yearly compensation is $1.62M, comprised of 37.5% salary and 62.5% bonuses, including company stock and options. directly owns 1.11% of the company’s shares, worth $17.26K. The average tenure of the management team and the board of directors is 3.9 years and 5.5 years respectively.

Key information

Jim Breitmeyer

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage37.5%
CEO tenure5.5yrs
CEO ownership1.1%
Management average tenure3.9yrs
Board average tenure5.5yrs

Recent management updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Recent updates

We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Jun 14
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation

Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Mar 03
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?

Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Nov 06
Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

Jul 12
Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Jan 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy

Oct 03

Oncternal Therapeutics begins phase 3 study of zilovertamab

Sep 27

Oncternal Therapeutics: Selling For Under Cash Value

Sep 02

Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M

Aug 09

Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Aug 07
Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation

Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study

Jul 14

Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve

Jun 07

We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Apr 12
We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate

Oncternal Therapeutics: Trading Near Cash With Impressive Results

Jan 04

Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Nov 09
Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans

Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company

Oct 10

Oncternal: Solid Data In 2 Cancers With High Unmet Need

Jun 17

We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

May 05
We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Jim Breitmeyer's remuneration changed compared to Oncternal Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$35m

Jun 30 2024n/an/a

-US$36m

Mar 31 2024n/an/a

-US$36m

Dec 31 2023US$2mUS$609k

-US$39m

Sep 30 2023n/an/a

-US$42m

Jun 30 2023n/an/a

-US$43m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$2mUS$580k

-US$44m

Sep 30 2022n/an/a

-US$41m

Jun 30 2022n/an/a

-US$39m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$5mUS$557k

-US$31m

Sep 30 2021n/an/a

-US$26m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$18m

Dec 31 2020US$780kUS$530k

-US$17m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$37m

Dec 31 2019US$1mUS$502k

-US$34m

Sep 30 2019n/an/a

-US$31m

Jun 30 2019n/an/a

-US$28m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$518kUS$426k

-US$7m

Compensation vs Market: Jim's total compensation ($USD1.62M) is above average for companies of similar size in the US market ($USD642.05K).

Compensation vs Earnings: Jim's compensation has been consistent with company performance over the past year.

CEO

Jim Breitmeyer (70 yo)

5.5yrs

Tenure

US$1,623,074

Compensation

Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...

Leadership Team

NamePositionTenureCompensationOwnership
James Breitmeyer
President5.5yrsUS$1.62m1.11%
$ 17.3k
Richard Vincent
CFO & Treasurer5.5yrsUS$847.91k0.25%
$ 3.9k
Rajesh Krishnan
Chief Technical & Scientific Officer3.9yrsno data0.074%
$ 1.2k
Chase Leavitt
General Counsel & Secretary3.7yrsno data0.14%
$ 2.2k
Pablo Urbaneja
Senior Vice President of Corporate Development3.4yrsno datano data

3.9yrs

Average Tenure

55.5yo

Average Age

Experienced Management: ONCT's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James Breitmeyer
President5.5yrsUS$1.62m1.11%
$ 17.3k
Michael Carter
Independent Director18.6yrsUS$59.80k0.12%
$ 1.9k
Daniel Kisner
Independent Director5.5yrsUS$67.50k0.017%
$ 263.2
William LaRue
Independent Director5.5yrsUS$67.00k0.044%
$ 688.7
David Hale
Independent Chairman of the Board5.5yrsUS$103.82k0.024%
$ 375.9
Rosemary Mazanet
Independent Director3.9yrsUS$61.32k0.00017%
$ 2.6
Thomas Kipps
Scientific Advisorno datano datano data
Charles Theuer
Independent Director5.5yrsUS$59.00k0.025%
$ 386.1
Robert Wills
Non-Independent Director5.5yrsUS$55.00k0.34%
$ 5.3k
Marcela Maus
Cell Therapy Scientific Advisory Board Member3.1yrsno datano data
Gunnar Kaufmann
Prostate Cancer & Cell Therapy Scientific Advisory Board Member1.9yrsUS$941.21k0.062%
$ 965.2
Michael Wang
Cell Therapy Scientific Advisory Board Member3.1yrsno datano data

5.5yrs

Average Tenure

70yo

Average Age

Experienced Board: ONCT's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/04 18:05
End of Day Share Price 2024/12/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Oncternal Therapeutics, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kaveri PohlmanBTIG
Li Wang WatsekCantor Fitzgerald & Co.
Carl ByrnesNorthland Capital Markets